Abstract
The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)
| Original language | English |
|---|---|
| Pages (from-to) | 1419-1426 |
| Number of pages | 8 |
| Journal | Clinical Therapeutics |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 2004 |
Fingerprint
Keywords
- antihypertensive treatment
- delapril
- enalapril
- essential hypertension
- hydrochlorothiazide
- manidipine
ASJC Scopus subject areas
- Pharmacology
Cite this
Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension : Results of a randomized trial. / Mugellini, Amedeo; Dobovisek, Jurij; Planinc, Danijel; Cremonesi, Giovanni; Fogari, Roberto.
In: Clinical Therapeutics, Vol. 26, No. 9, 09.2004, p. 1419-1426.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension
T2 - Results of a randomized trial
AU - Mugellini, Amedeo
AU - Dobovisek, Jurij
AU - Planinc, Danijel
AU - Cremonesi, Giovanni
AU - Fogari, Roberto
PY - 2004/9
Y1 - 2004/9
N2 - The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)
AB - The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)
KW - antihypertensive treatment
KW - delapril
KW - enalapril
KW - essential hypertension
KW - hydrochlorothiazide
KW - manidipine
UR - http://www.scopus.com/inward/record.url?scp=9744279749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9744279749&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2004.09.018
DO - 10.1016/j.clinthera.2004.09.018
M3 - Article
C2 - 15531004
AN - SCOPUS:9744279749
VL - 26
SP - 1419
EP - 1426
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 9
ER -